{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihvakvww3q5mhw4u5ydi5xey35idrcmjkae4q3iwg3hdxsamqgcw4",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3me7ad2ddtzq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibagzxay72wnp27blqf5pfrggvugmytun7afcf5fsivmcuzce6zte"
    },
    "mimeType": "image/jpeg",
    "size": 7865
  },
  "path": "/2026/02/06/neurophet-secures-fda-510k-clearance-for-neurophet-aqua-ad-plus-marking-its-third-u-s-regulatory-milestone/",
  "publishedAt": "2026-02-06T14:00:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet’s leadership in AI-based Alzheimer’s disease imaging analysis Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports imaging-based clinical decision-making and accelerates U.S. market expansion SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial […]",
  "title": "Neurophet Secures FDA 510(k) Clearance for “Neurophet AQUA AD Plus,” Marking Its Third U.S. Regulatory Milestone"
}